Clinical Trial

ProNephro NGAL Test for Early Detection of Acute Kidney Injury in Adult ICU Patients (ALPACA)

Study acronym: ALPACA
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the performance of the ProNephro AKI™ (NGAL) test for identifying critically ill adults at risk of developing moderate to severe acute kidney injury (KDIGO Stage 2/3) within 48 to 72 hours of ICU admission. The study will assess how accurately the test predicts acute kidney injury by evaluating its sensitivity, specificity, positive predictive value, and negative predictive value. Participants will provide blood and urine samples for testing.
Trial Details
NCT Number NCT07751913
Lead Sponsor BioPorto Diagnostics
Conditions Acute Kidney Injury
Enrollment 800 participants
Start Date 2026-08
Primary Completion 2027-11 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-10